Assess whether a CMO finding is a delay or a refuse-to-file risk (c69192)

Situation

The Pharmacovigilance desk packet is phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must name A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences file. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal has to name A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences Pharmacovigilance file.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose A CMO finding is a delay / A refuse-to-file risk using phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division.

Hypotheses to test

• Phase-3 protocol with endpoint-sensitivity issues reads as A CMO finding is a delay once a boxed-warning proposal from the review division is lined up to the same Pharma & Life Sciences population.
• Phase-3 protocol with endpoint-sensitivity issues is closer to A refuse-to-file risk after a boxed-warning proposal from the review division; A CMO finding is a delay would over-claim this Pharmacovigilance extract.
• A dual reading is still live in phase-3 protocol with endpoint-sensitivity issues for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.
• Phase-3 protocol with endpoint-sensitivity issues is missing the fact 505(b)(2) development lead needs after a boxed-warning proposal from the review division; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read phase-3 protocol with endpoint-sensitivity issues against a boxed-warning proposal from the review division and write the one fact that would move a CMO finding is for 505(b)(2) development lead.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Pharmacovigilance packet (phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division). If phase-3 protocol with endpoint-sensitivity issues cannot force a Pharma & Life Sciences label under Pharmacovigilance, stop. If phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division cannot support A CMO finding is a delay versus A refuse-to-file risk on this Pharma & Life Sciences Pharmacovigilance close, 505(b)(2) development lead must state the unresolved clinical or safety evidence requirement explicitly.